OBJECTIVE: Hepatitis C virus (HCV) is a major threat to public health in the United States. We describe and evaluate an HCV screening and linkage-to-care program, including emergency department, inpatient, and outpatient settings, in an urban safety-net health system in Chicago. METHODS: Sinai Health System implemented a universal HCV screening program in September 2016 that offered patient navigation services (ie, linkage to care) to patients with a positive result for HCV on an RNA test. We collected data from February 1, 2017, through January 31, 2019, on patient demographic characteristics, risk factors, and various outcomes (eg, number of patients screened, test results, proportions of new diagnoses, number of patients eligible for patient navigation services, and proportion of patients who attended their first medical appointment). We also examined outcomes by patients' knowledge of infection. RESULTS: Of 21 018 people screened for HCV, 6% (1318/21 018) had positive test results for HCV antibody, 68% (878/1293) of whom had positive HCV RNA test results. Of these 878 patients, 68% were born during 1945-1965, 68% were male, 65% were Black, 19% were Latino, 55% were newly diagnosed, and 64% were eligible for patient navigation services. Risk factors included past or current drug use (53%), unemployment (30%), and ever incarcerated (21%). Of 562 patients eligible for navigation services, 281 (50%) were navigated to imaging services, and 203 (72%) patients who completed imaging attended their first medical appointment. CONCLUSION: Patient navigation played a critical role in linkage success, but securing stable, long-term financial support for patient navigators is a challenge.
OBJECTIVE: Hepatitis C virus (HCV) is a major threat to public health in the United States. We describe and evaluate an HCV screening and linkage-to-care program, including emergency department, inpatient, and outpatient settings, in an urban safety-net health system in Chicago. METHODS: Sinai Health System implemented a universal HCV screening program in September 2016 that offered patient navigation services (ie, linkage to care) to patients with a positive result for HCV on an RNA test. We collected data from February 1, 2017, through January 31, 2019, on patient demographic characteristics, risk factors, and various outcomes (eg, number of patients screened, test results, proportions of new diagnoses, number of patients eligible for patient navigation services, and proportion of patients who attended their first medical appointment). We also examined outcomes by patients' knowledge of infection. RESULTS: Of 21 018 people screened for HCV, 6% (1318/21 018) had positive test results for HCV antibody, 68% (878/1293) of whom had positive HCV RNA test results. Of these 878 patients, 68% were born during 1945-1965, 68% were male, 65% were Black, 19% were Latino, 55% were newly diagnosed, and 64% were eligible for patient navigation services. Risk factors included past or current drug use (53%), unemployment (30%), and ever incarcerated (21%). Of 562 patients eligible for navigation services, 281 (50%) were navigated to imaging services, and 203 (72%) patients who completed imaging attended their first medical appointment. CONCLUSION: Patient navigation played a critical role in linkage success, but securing stable, long-term financial support for patient navigators is a challenge.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Arlene C Seña; Sarah J Willis; Alison Hilton; Alexandria Anderson; David A Wohl; Christopher B Hurt; Andrew J Muir Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Lesley S Miller; Francois Rollin; Shelly-Ann Fluker; Kristina L Lundberg; Brandi Park; Kristi Quairoli; Nyiramugisha K Niyibizi; Anne C Spaulding Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Alexander G Geboy; Sandeep Mahajan; Allison P Daly; Candice F Sewell; Ike C Fleming; Hyun A Cha; Idene E Perez; Carmella A Cole; Adebisi A Ayodele; Dawn A Fishbein Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Barbara S Taylor; Joshua T Hanson; Poornachand Veerapaneni; Roberto Villarreal; Kristin Fiebelkorn; Barbara J Turner Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Barbara J Turner; Barbara S Taylor; Joshua T Hanson; Mary Elizabeth Perez; Ludivina Hernandez; Roberto Villarreal; Poornachand Veerapaneni; Kristin Fiebelkorn Journal: J Hosp Med Date: 2015-05-29 Impact factor: 2.960
Authors: Gilberto Ramirez; Rebecca Cabral; Margaret Patterson; Ben T Schoenbachler; Deborah Bedell; Bryce D Smith; Claudia Vellozzi; Geoff A Beckett Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: James W Galbraith; Ricardo A Franco; John P Donnelly; Joel B Rodgers; Jordan M Morgan; Andres F Viles; Edgar T Overton; Michael S Saag; Henry E Wang Journal: Hepatology Date: 2015-01-28 Impact factor: 17.425
Authors: Douglas K Owens; Karina W Davidson; Alex H Krist; Michael J Barry; Michael Cabana; Aaron B Caughey; Katrina Donahue; Chyke A Doubeni; John W Epling; Martha Kubik; Gbenga Ogedegbe; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2020-03-10 Impact factor: 56.272